Relief Therapeutics Shareholders Approve Business Combination with NeuroX

AI SummaryClose X

Relief Therapeutics Holding SA shareholders overwhelmingly approved all proposals at an extraordinary general meeting, paving the way for a business combination with NeuroX Group SA to create a digital neurotherapeutics company. This combination involves an ordinary capital increase through the issuance of 140 million new ordinary shares in exchange for NeuroX shares, and the company will be renamed MindMaze Therapeutics Holding SA upon closing, expected in December 2025. New board members have been elected, and the combined entity will feature leadership from NeuroX, with Alexandre Capet as CEO and Frédéric Condolo as CTO.

Disclaimer*

UK 100

Latest directors dealings